Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLSEEK-3: BMS-986369 (Golcadomide) in Relapsed or Refractory T-cell Lymphomas in Japan
jRCT2061230061Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of golcadomide in non-Hodgkin lymphoma, T-cell, adult T-cell leukemia-lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Phase 1 safety and tolerability and RP2D, Phase 2 efficacy in ATL cohort and 1 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma, T-celladult T-cell leukemia-lymphoma (ATLL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT2061230061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230061.